Get the Stockscreener App
5.10
6.69%
0.32
After Hours:
5.09
-0.010
-0.20%
Pepgen Inc stock is traded at $5.10, with a volume of 182.46K.
It is up +6.69% in the last 24 hours and down -33.59% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$4.78
Open:
$4.78
24h Volume:
182.46K
Relative Volume:
1.75
Market Cap:
$178.30M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-1.7407
EPS:
-2.9299
Net Cash Flow:
$-82.77M
1W Performance:
+15.91%
1M Performance:
-33.59%
6M Performance:
-64.97%
1Y Performance:
+12.09%
1-Day Range:
$4.67
$5.98
1-Week Range:
$4.25
$5.98
52-Week Range:
$4.00
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
5.10 | 178.30M | 0 | -87.23M | -82.77M | -2.9299 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development - Business Wire
Two new option listings and one option delisting on November 21st - TipRanks
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Simply Wall St
BofA lowers PepGen stock target as trial delays and competition weigh on outlook - Investing.com
Bank of America Cuts PepGen (NASDAQ:PEPG) Price Target to $6.00 - MarketBeat
PepGen price target lowered to $6 from $10 at BofA - TipRanks
Janus Henderson Group PLC's Strategic Acquisition of PepGen Inc Shares - GuruFocus.com
Leerink Partnrs Issues Positive Forecast for PepGen Earnings - MarketBeat
PepGen (NASDAQ:PEPG) Price Target Cut to $12.00 by Analysts at Wedbush - MarketBeat
PepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC Wainwright - MarketBeat
PepGen Inc (PEPG) Quarterly 10-Q Report - Quartz
PepGen reports Q3 EPS (66c), consensus (87c) - TipRanks
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - BioSpace
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate - Yahoo Finance
Objective long/short (PEPG) Report - Stock Traders Daily
PepGen to Participate in Upcoming Investor Conferences - Business Wire
(PEPG) Technical Data - Stock Traders Daily
(PEPG) Proactive Strategies - Stock Traders Daily
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society - Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - Benzinga
When the Price of (PEPG) Talks, People Listen - Stock Traders Daily
PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024 - Marketscreener.com
PepGen director Christopher Ashton to retire at month's end - Investing.com
PepGen director Christopher Ashton to retire at month's end By Investing.com - Investing.com Australia
PepGen Inc. Board Reshuffles as Ashton Plans Retirement - TipRanks
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors - Business Wire
Sofinnova Investments Inc. Has $8.96 Million Holdings in PepGen Inc. (NASDAQ:PEPG) - MarketBeat
Investigation announced for Investors who lost money with - openPR
Trend Tracker for (PEPG) - Stock Traders Daily
PepGen Inc [NASDAQ: PEPG] Sees Decrease in Stock Value - Knox Daily
PepGen (NASDAQ:PEPG) Trading Down 0.4% - MarketBeat
(PEPG) Long Term Investment Analysis - Stock Traders Daily
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development - Manchestertimes
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development - Business Wire
The PepGen Inc (PEPG) had a good session last reading, didn’t it? - US Post News
A company insider recently sold 7,571 shares of PepGen Inc [PEPG]. Should You Sale? - Knox Daily
Metric Analysis: PepGen Inc (PEPG)’s Key Ratios in the Limelight - The Dwinnex
PepGen Inc (PEPG) Stock: A Year of Declines and Increases - The InvestChronicle
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - AccessWire
Vanguard Group Inc. Purchases 344,266 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
PepGen Inc. (NASDAQ:PEPG) Shares Purchased by Vanguard Group Inc. - MarketBeat
Investors Welcome To Participate In The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc - WICZ
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & - GlobeNewswire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - GlobeNewswire Inc.
FY2027 Earnings Forecast for PepGen Inc. Issued By HC Wainwright (NASDAQ:PEPG) - MarketBeat
FY2027 Earnings Estimate for PepGen Inc. (NASDAQ:PEPG) Issued By HC Wainwright - Defense World
PepGen Inc. Forecasted to Earn Q3 2024 Earnings of ($0.90) Per Share (NASDAQ:PEPG) - Defense World
Comparing PepGen (NASDAQ:PEPG) and Bicycle Therapeutics (NASDAQ:BCYC) - Defense World
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Business Wire
PEPG Investors Can Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm - AccessWire
PEPG (PepGen Inc) may reap gains as insiders became active recently - Knox Daily
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):